NO2021037I1 - evinakumab - Google Patents

evinakumab

Info

Publication number: NO2021037I1
Authority: NO; Norway
Prior art keywords: evinakumab
Prior art date: 2011-06-17

Application number

NO2021037C

Other languages

English (en)

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-17

Filing date

2021-09-15

Publication date

2021-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2021037(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-09-15 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2021-09-15 Publication of NO2021037I1 publication Critical patent/NO2021037I1/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO2021037C 2011-06-17 2021-09-15 evinakumab NO2021037I1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161498518P	2011-06-17	2011-06-17
US201161578309P	2011-12-21	2011-12-21
PCT/US2012/042338 WO2012174178A1 (en)	2011-06-17	2012-06-14	Anti-angptl3 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
NO2021037I1 true NO2021037I1 (no)	2021-09-15

Family

ID=46298728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO2021037C NO2021037I1 (no)	2011-06-17	2021-09-15	evinakumab

Country Status (45)

Country	Link
US (7)	US9018356B2 (no)
EP (2)	EP2721065B1 (no)
JP (2)	JP6400471B2 (no)
KR (1)	KR102031007B1 (no)
CN (1)	CN103732624B (no)
AR (1)	AR087329A1 (no)
AU (1)	AU2012271663B2 (no)
CA (1)	CA2838867C (no)
CL (1)	CL2013003552A1 (no)
CO (1)	CO6821892A2 (no)
CR (1)	CR20130621A (no)
CY (2)	CY1120996T1 (no)
DK (1)	DK2721065T3 (no)
DO (1)	DOP2013000299A (no)
EC (1)	ECSP13013085A (no)
ES (1)	ES2699499T3 (no)
FI (1)	FIC20210028I1 (no)
GT (1)	GT201300306A (no)
HR (1)	HRP20182098T1 (no)
HU (1)	HUS2100034I1 (no)
IL (2)	IL229612B (no)
JO (1)	JO3412B1 (no)
LT (2)	LT2721065T (no)
LU (1)	LUC00231I2 (no)
MA (1)	MA35190B1 (no)
MX (2)	MX337644B (no)
MY (1)	MY160516A (no)
NI (1)	NI201300136A (no)
NL (1)	NL301122I2 (no)
NO (1)	NO2021037I1 (no)
PE (1)	PE20141166A1 (no)
PH (1)	PH12013502570B1 (no)
PL (1)	PL2721065T3 (no)
PT (1)	PT2721065T (no)
RS (1)	RS58310B1 (no)
RU (1)	RU2620064C2 (no)
SG (1)	SG195165A1 (no)
SI (1)	SI2721065T1 (no)
SM (1)	SMT201800658T1 (no)
TR (1)	TR201816591T4 (no)
TW (3)	TW201815822A (no)
UA (1)	UA114891C2 (no)
UY (2)	UY39340A (no)
WO (1)	WO2012174178A1 (no)
ZA (1)	ZA201308879B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR087329A1 (es) *	2011-06-17	2014-03-19	Regeneron Pharma	Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
AR095196A1 (es)	2013-03-15	2015-09-30	Regeneron Pharma	Medio de cultivo celular libre de suero
WO2017011929A1 (zh) *	2015-07-17	2017-01-26	北京大学第一医院	检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW202440904A (zh)	2015-08-04	2024-10-16	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法（二）
TW201713690A (zh)	2015-08-07	2017-04-16	再生元醫藥公司	抗ａｎｇｐｔｌ８抗體及其用途
MD3416684T2 (ro) *	2016-02-17	2023-10-31	Regeneron Pharma	Metode de tratament sau prevenire a aterosclerozei prin administrarea unui inhibitor al ANGPTL3
KR102456731B1 (ko)	2016-03-03	2022-10-24	리제너론 파아마슈티컬스, 인크.	Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
MX386832B (es) *	2016-04-08	2025-03-19	Regeneron Pharma	Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia.
EP3448426B1 (en) *	2016-04-28	2025-05-28	Regeneron Pharmaceuticals, Inc.	Methods for treating patients with familial hypercholesterolemia
WO2018039499A1 (en)	2016-08-24	2018-03-01	Regeneron Pharmaceuticals, Inc.	Host cell protein modification
WO2018094112A1 (en)	2016-11-17	2018-05-24	Regeneron Pharmaceuticals, Inc.	Methods of treating obesity with anti-angptl8 antibodies
EP3649144A4 (en)	2017-07-06	2021-07-21	Regeneron Pharmaceuticals, Inc.	CELL CULTURE PROCESS TO PRODUCE GLYCOPROTEIN
US11977081B2 (en)	2017-12-18	2024-05-07	Regeneron Pharmaceuticals, Inc.	ANGPTL8 assay and uses thereof
CN111479618B (zh)	2017-12-22	2022-08-02	瑞泽恩制药公司	用于表征药物产品杂质的系统和方法
JP7349998B2 (ja)	2018-01-31	2023-09-25	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
TWI786265B (zh)	2018-02-02	2022-12-11	美商再生元醫藥公司	用於表徵蛋白質二聚合之系統及方法
SG11202006310PA (en)	2018-02-28	2020-07-29	Regeneron Pharma	Systems and methods for identifying viral contaminants
FI3768709T3 (fi)	2018-03-19	2024-02-01	Regeneron Pharma	Mikrosirukapillaarielektroforeesianalyysejä ja -reagensseja
US12259355B2 (en)	2018-03-19	2025-03-25	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
US12253490B2 (en)	2018-03-19	2025-03-18	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
TW202016125A (zh)	2018-05-10	2020-05-01	美商再生元醫藥公司	用於定量及調節蛋白質黏度之系統與方法
EP3774841A1 (en)	2018-08-27	2021-02-17	Regeneron Pharmaceuticals, Inc.	Use of raman spectroscopy in downstream purification
EA202190032A1 (ru)	2018-08-30	2021-03-12	Ридженерон Фармасьютикалз, Инк.	Способы определения характеристик белковых комплексов
JP2022513626A (ja) *	2018-11-26	2022-02-09	ノバルティスアーゲー	Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
TWI747098B (zh) *	2018-12-21	2021-11-21	美商美國禮來大藥廠	抗angptl3/8複合物抗體及其使用方法
EP3857237B1 (en)	2019-01-16	2023-03-01	Regeneron Pharmaceuticals, Inc.	Methods for characterizing disulfide bonds
WO2020185952A1 (en) *	2019-03-11	2020-09-17	xCella Biosciences, Inc.	Cd27-binding antibodies and uses thereof
CA3135004A1 (en)	2019-05-13	2020-11-19	Regeneron Pharmaceuticals, Inc.	Improved competitive ligand binding assays
US20200369760A1 (en) *	2019-05-24	2020-11-26	Regeneron Pharmaceuticals, Inc.	Stabilized formulations containing anti-angptl3 antibodies
CN112062845B (zh) *	2019-06-10	2022-09-02	山东博安生物技术股份有限公司	Angptl3结合片段及其用途
EP3993820A4 (en) *	2019-07-04	2023-08-16	Cadila Healthcare Limited	VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
IL291020B2 (en)	2019-09-24	2025-04-01	Regeneron Pharma	Systems and methods for use in chromatography and regeneration
US12297451B1 (en)	2019-10-25	2025-05-13	Regeneron Pharmaceuticals, Inc.	Cell culture medium
EP4065086A1 (en)	2019-11-25	2022-10-05	Regeneron Pharmaceuticals, Inc.	Sustained release formulations using non-aqueous emulsions
CN110938144B (zh) *	2019-11-27	2022-07-26	复旦大学附属儿科医院	一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
WO2021150558A1 (en)	2020-01-21	2021-07-29	Regeneron Pharmaceuticals, Inc.	Deglycosylation methods for electrophoresis of glycosylated proteins
AU2021209746A1 (en) *	2020-01-22	2022-08-25	Jiangsu Hengrui Medicine Co., Ltd.	Anti-ANGPTL3 antibody and use thereof
CA3192999A1 (en)	2020-08-31	2022-03-03	Regeneron Pharmaceuticals, Inc.	Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
JP2023551446A (ja)	2020-11-25	2023-12-08	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	非水膜乳化を使用した持続放出製剤
CN116710124A (zh)	2020-12-17	2023-09-05	瑞泽恩制药公司	包封蛋白质的微凝胶的制造
WO2022159432A1 (en)	2021-01-20	2022-07-28	Regeneron Pharmaceuticals, Inc.	Methods of improving protein titer in cell culture
KR20230150300A (ko)	2021-03-03	2023-10-30	리제너론 파마슈티칼스 인코포레이티드	단백질 점도를 정량화하고 변경시키기 위한 시스템 및 방법
US20240141029A1 (en) *	2021-03-05	2024-05-02	Anji Pharmaceuticals Inc.	Methods and compositions for treating sepsis
EP4315344A1 (en)	2021-03-26	2024-02-07	Regeneron Pharmaceuticals, Inc.	Methods and systems for developing mixing protocols
WO2022205021A1 (zh) *	2021-03-30	2022-10-06	复旦大学附属儿科医院	一种抗angptl3抗体或其抗原结合片段及其制备方法和用途
MX2023014246A (es)	2021-06-01	2024-01-17	Regeneron Pharma	Ensayos y reactivos de microchips de electroforesis capilar.
AU2022314036A1 (en) *	2021-07-21	2024-02-01	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
TW202326138A (zh)	2021-09-08	2023-07-01	美商再生元醫藥公司	用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
CA3232463A1 (en)	2021-09-20	2023-03-23	Philip Mellors	Methods of controlling antibody heterogeneity
EP4413359A1 (en)	2021-10-07	2024-08-14	Regeneron Pharmaceuticals, Inc.	Ph meter calibration and correction
TW202323817A (zh)	2021-10-07	2023-06-16	美商再生元醫藥公司	Ｐｈ建模及控制之系統及方法
AU2022376179A1 (en)	2021-10-26	2024-05-16	Regeneron Pharmaceuticals, Inc.	Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN116284377A (zh) *	2021-12-21	2023-06-23	复旦大学	抗人血管生成素3纳米抗体及其应用
JP2025500414A (ja) *	2021-12-22	2025-01-09	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	アンジオポエチン様３（ａｎｇｐｔｌ３）阻害剤による腎疾患の治療
EP4493921A1 (en)	2022-03-18	2025-01-22	Regeneron Pharmaceuticals, Inc.	Methods and systems for analyzing polypeptide variants
AR129198A1 (es) *	2022-05-02	2024-07-31	Novo Nordisk As	Nuevos anticuerpos anti-angptl3 adecuados para composiciones de concentración alta
CN117603361A (zh) *	2022-08-22	2024-02-27	复旦大学附属儿科医院	包含angptl3单抗的融合蛋白
CN116143919B (zh) *	2022-11-01	2025-06-13	中国药科大学	全人源抗人nt-angptl3抗体、其抗原结合片段及其应用
WO2024130165A1 (en)	2022-12-16	2024-06-20	Regeneron Pharmaceuticals, Inc.	Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
TW202435942A (zh)	2022-12-16	2024-09-16	美商里珍納龍藥品有限公司	評估層析管柱完整性的方法及系統
US20240245779A1 (en)	2023-01-25	2024-07-25	Regeneron Pharmaceuticals, Inc.	Methods of modeling liquid protein composition stability
WO2024158961A1 (en)	2023-01-25	2024-08-02	Regeneron Pharmaceuticals, Inc.	Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445138A (zh)	2023-02-01	2024-11-16	美商再生元醫藥公司	用於生物巨分子分析之具質譜法的不對稱流場流分離
US20240280551A1 (en)	2023-02-22	2024-08-22	Regeneron Pharmaceuticals, Inc.	System suitability parameters and column aging
WO2024229136A1 (en)	2023-05-01	2024-11-07	Regeneron Pharmaceuticals, Inc.	Multidose antibody drug products using phenol or benzyl alcohol
CN119192369A (zh) *	2023-06-25	2024-12-27	百奥泰生物制药股份有限公司	抗angptl3抗体及其应用
US20250086164A1 (en)	2023-09-08	2025-03-13	Regeneron Pharmaceuticals, Inc.	Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en)	2023-09-18	2025-03-27	Regeneron Pharmaceuticals, Inc.	Methods and systems for developing chromatography protocols
US20250109905A1 (en)	2023-09-29	2025-04-03	Regeneron Pharmaceuticals, Inc.	Lyophilization using controlled nucleation
CN117535353A (zh) *	2023-10-11	2024-02-09	首都医科大学附属北京潞河医院	一种糖尿病视网膜病变模型的建立方法及应用
US20250129117A1 (en)	2023-10-18	2025-04-24	Regeneron Pharmaceuticals, Inc.	Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en)	2023-11-02	2025-05-08	Regeneron Pharmaceuticals, Inc.	Methods for reducing lipase activity using stress

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020035058A1 (en)	1996-05-15	2002-03-21	The University Of Sheffield	Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en)	1997-09-19	2000-02-29	Genetech, Inc.	Tie ligand homologues
US7070959B1 (en)	1999-06-08	2006-07-04	Regeneron Pharmaceuticals, Inc.	Modified chimeric polypeptides with improved pharmacokinetic properties
DE60127457T2 (de)	2001-02-22	2007-11-29	Jagotec Ag	Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
JP5105696B2 (ja)	2001-11-16	2012-12-26	ジェネンテック，インコーポレイテッド	アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法
EP2322201A3 (en)	2002-10-29	2011-07-27	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US20040101920A1 (en)	2002-11-01	2004-05-27	Czeslaw Radziejewski	Modification assisted profiling (MAP) methodology
JP2005080508A (ja)	2003-09-04	2005-03-31	Sankyo Co Ltd	脂質代謝改善剤の試験方法
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
WO2006098887A2 (en)	2005-03-11	2006-09-21	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
ES2400666T5 (es)	2005-12-16	2016-03-10	Regeneron Pharmaceuticals, Inc.	Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
DK2041177T3 (da)	2006-06-02	2012-02-27	Regeneron Pharma	Højaffinitetsantistoffer mod human IL-6-receptor
MEP11109A (en) *	2006-10-02	2011-12-20		High affinity human antibodies to human il-4 receptor
WO2008073300A2 (en) *	2006-12-08	2008-06-19	Lexicon Pharmaceuticals, Inc.	Monoclonal antibodies against angptl3
RU2448979C2 (ru)	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en)	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (en)	2009-02-06	2010-08-11	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising ezetimibe
CN101852805B (zh)	2009-03-31	2015-04-01	浙江大学	Angptl3作为卵巢癌的诊断标记物的用途
MA33423B1 (fr)	2009-07-14	2012-07-03	Scripps Research Inst	Différentiation de cellules souches mésenchymateuses
US8653047B2 (en)	2010-01-08	2014-02-18	Isis Pharmaceuticals, Inc.	Modulation of angiopoietin-like 3 expression
AR087329A1 (es)	2011-06-17	2014-03-19	Regeneron Pharma	Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
BR112013033260B1 (pt) *	2011-06-21	2022-06-21	Alnylam Pharmaceuticals	Ácido ribonucleico de fita dupla (dsrna) para inibir a expressão de angptl3, composição farmacêutica e método in vitro para inibir a expressão de angptl3 em uma célula
US10111953B2 (en)	2013-05-30	2018-10-30	Regeneron Pharmaceuticals, Inc.	Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
KR102298476B1 (ko)	2013-12-24	2021-09-03	아이오니스 파마수티컬즈, 인코포레이티드	안지오포이에틴-유사 3 발현의 조절
KR102356388B1 (ko)	2014-05-01	2022-01-26	아이오니스 파마수티컬즈, 인코포레이티드	안지오포이에틴-유사 3 발현을 조절하기 위한 조성물 및 방법
KR20230074283A (ko)	2014-07-16	2023-05-26	사노피 바이오테크놀로지	이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
TW201713690A (zh)	2015-08-07	2017-04-16	再生元醫藥公司	抗ａｎｇｐｔｌ８抗體及其用途
MD3416684T2 (ro)	2016-02-17	2023-10-31	Regeneron Pharma	Metode de tratament sau prevenire a aterosclerozei prin administrarea unui inhibitor al ANGPTL3
KR102456731B1 (ko)	2016-03-03	2022-10-24	리제너론 파아마슈티컬스, 인크.	Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
MX386832B (es)	2016-04-08	2025-03-19	Regeneron Pharma	Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia.
EP3448426B1 (en)	2016-04-28	2025-05-28	Regeneron Pharmaceuticals, Inc.	Methods for treating patients with familial hypercholesterolemia
US20200369760A1 (en) *	2019-05-24	2020-11-26	Regeneron Pharmaceuticals, Inc.	Stabilized formulations containing anti-angptl3 antibodies

2012
- 2012-06-13 AR ARP120102099A patent/AR087329A1/es active IP Right Grant
- 2012-06-13 JO JOP/2012/0155A patent/JO3412B1/ar active
- 2012-06-14 PL PL12727767T patent/PL2721065T3/pl unknown
- 2012-06-14 EP EP12727767.1A patent/EP2721065B1/en active Active
- 2012-06-14 MX MX2013014345A patent/MX337644B/es active IP Right Grant
- 2012-06-14 EP EP18185031.4A patent/EP3418301A1/en not_active Withdrawn
- 2012-06-14 PE PE2013002804A patent/PE20141166A1/es active IP Right Grant
- 2012-06-14 TR TR2018/16591T patent/TR201816591T4/tr unknown
- 2012-06-14 LT LTEP12727767.1T patent/LT2721065T/lt unknown
- 2012-06-14 WO PCT/US2012/042338 patent/WO2012174178A1/en active Application Filing
- 2012-06-14 KR KR1020147000902A patent/KR102031007B1/ko active Active
- 2012-06-14 SI SI201231444T patent/SI2721065T1/sl unknown
- 2012-06-14 MY MYPI2013004223A patent/MY160516A/en unknown
- 2012-06-14 HR HRP20182098TT patent/HRP20182098T1/hr unknown
- 2012-06-14 PT PT12727767T patent/PT2721065T/pt unknown
- 2012-06-14 CN CN201280038908.0A patent/CN103732624B/zh active Active
- 2012-06-14 RU RU2013155906A patent/RU2620064C2/ru active
- 2012-06-14 US US13/517,662 patent/US9018356B2/en active Active
- 2012-06-14 UA UAA201314628A patent/UA114891C2/uk unknown
- 2012-06-14 JP JP2014515976A patent/JP6400471B2/ja active Active
- 2012-06-14 DK DK12727767.1T patent/DK2721065T3/en active
- 2012-06-14 SG SG2013087432A patent/SG195165A1/en unknown
- 2012-06-14 MX MX2015017575A patent/MX361859B/es unknown
- 2012-06-14 ES ES12727767T patent/ES2699499T3/es active Active
- 2012-06-14 AU AU2012271663A patent/AU2012271663B2/en active Active
- 2012-06-14 CA CA2838867A patent/CA2838867C/en active Active
- 2012-06-14 SM SM20180658T patent/SMT201800658T1/it unknown
- 2012-06-14 PH PH1/2013/502570A patent/PH12013502570B1/en unknown
- 2012-06-14 RS RS20181508A patent/RS58310B1/sr unknown
- 2012-06-15 TW TW106123582A patent/TW201815822A/zh unknown
- 2012-06-15 TW TW101121453A patent/TWI644922B/zh active
- 2012-06-15 TW TW107135714A patent/TW201920261A/zh unknown
- 2012-06-15 UY UY0001039340A patent/UY39340A/es not_active Application Discontinuation
- 2012-06-15 UY UY0001034137A patent/UY34137A/es not_active Application Discontinuation
2013
- 2013-11-25 IL IL229612A patent/IL229612B/en active IP Right Grant
- 2013-11-26 CR CR20130621A patent/CR20130621A/es unknown
- 2013-11-26 ZA ZA2013/08879A patent/ZA201308879B/en unknown
- 2013-12-06 NI NI201300136A patent/NI201300136A/es unknown
- 2013-12-11 CL CL2013003552A patent/CL2013003552A1/es unknown
- 2013-12-11 GT GT201300306A patent/GT201300306A/es unknown
- 2013-12-11 DO DO2013000299A patent/DOP2013000299A/es unknown
- 2013-12-13 CO CO13292222A patent/CO6821892A2/es unknown
- 2013-12-16 EC ECSP13013085 patent/ECSP13013085A/es unknown
- 2013-12-17 MA MA36579A patent/MA35190B1/fr unknown
2015
- 2015-03-24 US US14/667,121 patent/US9951127B2/en active Active
2018
- 2018-04-20 US US15/958,996 patent/US10358487B2/en active Active
- 2018-05-16 IL IL259436A patent/IL259436A/en active IP Right Grant
- 2018-07-06 JP JP2018128768A patent/JP2018166516A/ja active Pending
- 2018-12-11 CY CY181101324T patent/CY1120996T1/el unknown
2019
- 2019-06-07 US US16/435,032 patent/US20190315851A1/en not_active Abandoned
2021
- 2021-09-01 NL NL301122C patent/NL301122I2/nl unknown
- 2021-09-06 LT LTPA2021009C patent/LTC2721065I2/lt unknown
- 2021-09-06 HU HUS2100034C patent/HUS2100034I1/hu unknown
- 2021-09-09 FI FIC20210028C patent/FIC20210028I1/fi unknown
- 2021-09-15 NO NO2021037C patent/NO2021037I1/no unknown
- 2021-09-23 LU LU00231C patent/LUC00231I2/fr unknown
- 2021-12-06 CY CY2021036C patent/CY2021036I2/el unknown
2022
- 2022-01-27 US US17/586,662 patent/US20220153825A1/en not_active Abandoned
- 2022-09-08 US US17/930,704 patent/US20220403016A1/en not_active Abandoned
2024
- 2024-12-27 US US19/004,070 patent/US20250136675A1/en active Pending

Also Published As

Publication number	Publication date
JO3412B1 (ar)	2019-10-20
SI2721065T1 (sl)	2018-12-31
SG195165A1 (en)	2013-12-30
TR201816591T4 (tr)	2018-11-21
AR087329A1 (es)	2014-03-19
RU2620064C2 (ru)	2017-05-22
RS58310B1 (sr)	2019-03-29
US20190092845A1 (en)	2019-03-28
ECSP13013085A (es)	2014-01-31
FIC20210028I1 (fi)	2021-09-09
NL301122I1 (no)	2021-09-01
JP2014523739A (ja)	2014-09-18
CY2021036I1 (el)	2022-03-24
GT201300306A (es)	2015-03-09
WO2012174178A1 (en)	2012-12-20
KR20140037218A (ko)	2014-03-26
CN103732624B (zh)	2016-08-17
JP6400471B2 (ja)	2018-10-03
TW201815822A (zh)	2018-05-01
CN103732624A (zh)	2014-04-16
US9018356B2 (en)	2015-04-28
JP2018166516A (ja)	2018-11-01
MX337644B (es)	2016-03-14
ES2699499T3 (es)	2019-02-11
MA35190B1 (fr)	2014-06-02
US20150197564A1 (en)	2015-07-16
SMT201800658T1 (it)	2019-01-11
UY34137A (es)	2013-01-03
ZA201308879B (en)	2014-07-30
CA2838867A1 (en)	2012-12-20
CO6821892A2 (es)	2013-12-31
US20190315851A1 (en)	2019-10-17
UA114891C2 (uk)	2017-08-28
IL229612B (en)	2019-06-30
TW201920261A (zh)	2019-06-01
IL229612A0 (en)	2014-01-30
UY39340A (es)	2021-08-31
AU2012271663B2 (en)	2017-04-20
TWI644922B (zh)	2018-12-21
MY160516A (en)	2017-03-15
EP3418301A1 (en)	2018-12-26
AU2012271663A1 (en)	2014-01-16
HRP20182098T1 (hr)	2019-02-08
PE20141166A1 (es)	2014-09-16
MX2013014345A (es)	2014-01-31
US10358487B2 (en)	2019-07-23
US20220153825A1 (en)	2022-05-19
LTPA2021009I1 (no)	2021-09-27
DK2721065T3 (en)	2018-12-03
IL259436A (en)	2018-07-31
CY2021036I2 (el)	2022-05-27
US20220403016A1 (en)	2022-12-22
CA2838867C (en)	2020-07-14
LT2721065T (lt)	2018-12-10
PT2721065T (pt)	2018-12-06
DOP2013000299A (es)	2014-04-15
CL2013003552A1 (es)	2014-07-25
MX361859B (es)	2018-12-18
NI201300136A (es)	2014-05-15
TW201313738A (zh)	2013-04-01
NZ619092A (en)	2016-03-31
EP2721065B1 (en)	2018-09-12
EP2721065A1 (en)	2014-04-23
HUS2100034I1 (hu)	2021-10-28
LUC00231I2 (no)	2025-02-03
CR20130621A (es)	2014-02-12
PL2721065T3 (pl)	2019-02-28
PH12013502570A1 (en)	2014-01-27
RU2013155906A (ru)	2015-07-27
US9951127B2 (en)	2018-04-24
LTC2721065I2 (no)	2022-10-25
PH12013502570B1 (en)	2019-01-16
CY1120996T1 (el)	2019-12-11
NL301122I2 (nl)	2021-12-30
US20250136675A1 (en)	2025-05-01
US20130171149A1 (en)	2013-07-04
KR102031007B1 (ko)	2019-11-08

Publication	Publication Date	Title
NO2021037I1 (no)	2021-09-15	evinakumab
DK2744810T4 (da)	2023-11-20	Tenofovir-alafenamid-hemifumarat
EP2780065A4 (en)	2015-05-27	NASAL MASK SYSTEM
EP2768410A4 (en)	2015-09-02	EXTENSION COLLAR SYSTEM
EP2664141A4 (en)	2013-12-11	UNBLOCKING FILTERING
DK2769050T3 (da)	2021-05-17	Propsensor
EP2748335A4 (en)	2015-05-06	BIOLOGICAL MARKERS OF URINE
DE102011100082A8 (de)	2013-01-10	Traygreifvorrichtung
BR112014000879A2 (pt)	2017-02-21	deflegmador
EP2795884A4 (en)	2015-07-29	Audio conferencing
DK3272861T3 (da)	2020-03-23	Alpha-galactosidase-sammensætninger
CO6960543A2 (es)	2014-05-30	2-tiopirimidinonas
EP2786752A4 (en)	2015-05-06	Ropinirole-containing adhesive patch
EP2768739A4 (en)	2015-10-21	EYEWASH FLUID CONTAINER
DK3141251T3 (da)	2021-02-01	Koloskopi - forberedelse
EP2708561A4 (en)	2014-09-24	BIO-PIN
EP2738148A4 (en)	2015-05-27	RECIPROCAL LOCKING BLOCK
EP2760803A4 (en)	2015-07-08	Geopolymer product
EP2771685A4 (en)	2015-10-21	BIOMARKERS OF CANCER
EP2788163A4 (en)	2015-10-21	POST-MOLDING SYSTEM
EP2729467A4 (en)	2014-05-14	CRYPTATE COMPOUNDS
EP2698098A4 (en)	2014-10-29	campimeter
DK2476953T3 (da)	2020-05-11	Fluidbedkedel
DE112012002458A5 (de)	2014-02-27	Hydrotransformator
FI9371U1 (fi)	2011-08-31	Liuospussin kannatin